Claims for Patent: 11,980,674

Summary for Patent: 11,980,674

Title:	Imaging of metastatic or recurrent cancer
Abstract:	The present disclosure relates to methods of administering [18F]-FACBC. The present disclosure also relates to use of [18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer.
Inventor(s):	Eugene TEOH, Matthew Miller, Peter Gardiner
Assignee:	Blue Earth Diagnostics Ltd
Application Number:	US17/350,104
Patent Claims:	1. A method of using anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid ([18F]-FACBC) for a positron emission tomography (PET) scan, comprising: a) administering the [18F]-FACBC as an intravenous bolus injection into a human subject; and b) acquiring a PET scan image of at least a pelvic region of the subject; wherein the subject has i) for at least 4 hours prior to the administration of the [18F]-FACBC, consumed no food or drink including water, except sips of water for taking medications, ii) voided their bladder approximately 30 minutes to 60 minutes prior to the administration of the [18F]-FACBC and iii) then refrained from voiding their bladder until after the PET scan has been completed. 2. The method of claim 1, wherein the [18F]-FACBC is administered into the arm of the subject. 3. The method of claim 1, wherein the subject has avoided significant exercise from the day before the PET scan through to the time of the PET scan. 4. The method of claim 1, wherein the PET scan starts 3 to 5 minutes after the end of the injection of the [18F]-FACBC. 5. The method of claim 1, wherein the subject has a suspected prostate cancer recurrence. 6. The method of claim 1, wherein between 250 MBq and 500 MBq of the [18F]-FACBC is administered. 7. The method of claim 1, wherein between 290 MBq and 450 MBq of the [18F]-FACBC is administered. 8. The method of claim 1, wherein 370+/−20% MBq of the [18F]-FACBC is administered. 9. The method of claim 8, wherein 370 MBq of the [18F]-FACBC is administered. 10. The method of claim 1, wherein the [18F]-FACBC is diluted prior to injection. 11. The method of claim 10, wherein the [18F]-FACBC is diluted up to 10 mL. 12. The method of claim 1, wherein the subject is in a supine position with arms of the subject above the head of the subject when acquiring the PET scan image. 13. The method claim 1, wherein acquiring the PET scan image includes scanning from a proximal thigh to a base of the skull of the subject. 14. The method of claim 1, wherein the acquired PET scan image includes the proximal thigh. 15. The method of claim 1, further comprising analysing the PET scan image for a lesion less than 1 cm in a location suspicious for prostate cancer recurrence and having an [18F]-FACBC uptake greater than blood pool. 16. The method of claim 15, further comprising identifying the lesion as suspicious for the prostate cancer recurrence. 17. The method of claim 1, wherein the [18F]-FACBC is administered into the right arm of the subject. 18. A method of treating a human subject, comprising: a) administering anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid ([18F]-FACBC) as an intravenous bolus injection into the subject, wherein the subject has: consumed no food or drink including water except sips of water for taking medications for at least 4 hours prior to the administration of the [18F]-FACBC; and voided their bladder 30 to 60 minutes before the administration of the [18F]-FACBC and b) acquiring a positron emission tomography (PET) scan image of at least a pelvic region of the subject, wherein the subject refrains from voiding their bladder until after acquiring the PET scan image has been completed.